Cite
HARVARD Citation
Geoerger, B. et al. (2020). Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet oncology. 21 (1), pp. 121-133. [Online].